You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Boston Scientific’s Ingenio pacemaker wins FDA approval

Boston Scientific Corp.’s Ingenio and Advantio pacemakers won US approval to treat abnormally slow heartbeats, clearing the way for sales of devices that have been in development for a decade.

The pacemakers are designed to help the heart adjust to demands from physical exercise and ease shortness of breath during walking, climbing stairs, or other activities. The Natick-based company said it also gained Food and Drug Administration clearance for the Invive pacemaker, used to help synchronize cardiac contractions in heart failure patients.

Continue reading below

The Ingenio system is key to an “increasingly compelling product pipeline” expected to boost sales starting in 2013, said Rick Wise, a Leerink Swann & Co. analyst in New York, in an investor note. The early approval, given before the Heart Rhythm Society meets this week in Boston, will help the company spread the word about the entries into a $4 billion pacemaker market.

“It has a lot of new features that put us squarely even with and, in important respects, ahead of what the competition can offer,” said Ken Stein, chief medical officer for Boston Scientific’s cardiac rhythm management group, by telephone. “We are starting to deliver on the product turnaround and a complete refresh of our product pipeline.”

Boston Scientific and competitors have faced slowing sales of defibrillators, used to shock a stopped heart back into a normal rhythm, and drug-coated stents that hold open clogged arteries after they’ve been cleared. While pacemaker sales have been stable, newer products such as Medtronic Inc.’s Revo MRI SureScan pacing system that is safe with advanced imaging procedures have captured additional market share.

The Ingenio and Invive devices monitor respiratory rate in addition to the heartbeat, providing doctors with information on an early warning signal for a weakening heart, Stein said. Breathing rates typically rise, even when patients are resting, as their hearts falter and they have trouble getting oxygen, he said. The respiration rate is an important vital sign that doctors will be able to track over time, he said.

All three devices were designed to work with the company’s experimental Latitude NXT Remote Patient Management System. The system uses a wireless connection to take daily reading from patients after they are in bed and send the results to their doctors, adding an additional layer of information and protection to their regular office visits, Stein said.

The Ingenio system was approved based on a Boston Scientific study conducted in Europe, where it was cleared last month. The company is working on a version of the pacemaker that is safe for patients to undergo magnetic resonance imaging without losing any of the functions that help doctors and patients manage the heart, Stein said.

Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.